1MPALARIS V,ANAGNOSTIS P,GOULIS D G,et al. Complex as- sociation between body weight and fracture risk in postmenopausal women[J]. Obesity Rev,2015,16(3) :225-233.
2METGE C J, LESLIE W D, MANNESS L J,et al. Postfracture care for older women : gaps between optimal care and actual care ~ 31. Can Fam Physician,2008,54(9 ) :1270-1276.
3CARRADORI S, MOLLICA A, DE MONTE C,et al. Nitric oxide donors and selective carbonic anhydrase inhibitors:a dual pharma-cological approach for the treatment of glaucoma, cancer and osteo- porosis[ J]. Molecules ,2015,20(4) :5667-5679.
4JOHNELL O, KANIS J A. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures [ J ]. Osteoporos lnt ,2006,17 (12) : 1726-1733.
5GULLBER B, JOHNELL O, KANIS J A. World-wide projections for hip fracture [ J ]. Osteoporos lnt, 1997,7 (5) :407-413.
6IAMAL S A, HAMILTON C J. Nitric oxide donors for the treatment of osteoporosis[ J]. Curr Osteoporos Rep ,2012 ,10( 1 ) :86-92.
7SATTERWITHE J, HEATHMAN M, MILLER P D, et al. Pharma- cokinetics of teriparatide[rhPTH(1-34)1 and calcium pharmaco- dynamics in postmenopausalwomen with osteoporosis [ J ]. Calcif Tissue Int,2010,87(6) :485-492.
8VAI-ILE J L,LONG G G,SANDUSKY G,et al. Bone neoplasms in F344 rats given teriparatide [ rhPTH (1-34 ) ] are dependent on du- ration of treatment and dose [ J ]. Toxicol Pathol, 2004,32 ( 4 ) : 426-438.
9MILLER P D. Safety of parathyroid hormone for the treatment of os- teoporosis[ J ]. Curr Osteoporos Rep ,2008,6 ( 1 ) : 12-16.
10MAJUMDAR S R,MCALISTER F A,JOHNSON J A,et al. Criti- cal impact of patient knowledge and bone density testing on start- ing osteoporosis treatment after fragility fracture:secondary analy- ses from two controlled trials [ J ]. Osteoporos lut, 2014,25 ( 9 ) : 2173-2179.
